Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 137, Issue , 2018, Pages 83-92

  El Masri, Dana ^a   Ghosh, Samiran ^a   Jaber, Linda A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Meta analysis; Sodium glucose cotransporter 2 inhibitors; Systematic review; Type 1 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; BODY WEIGHT LOSS; DIABETIC KETOACIDOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNGAL GENITAL INFECTION; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LOW DRUG DOSE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85041621110     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2018.01.004     Document Type: Review

References (54)

1. Type 1 diabetes facts. Juvenile diabetes research foundation. http://www.jdrf.org/about/fact-sheets/type-1-diabetes-facts/ [accessed 5.5.17].
2. National Diabetes Statistics Report. Centers for diabetes control and prevention. https://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html [accessed 5.5.17].
3. Impreatore, G., Boyle, J.P., Thompson, T.J., et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050. Diabetes Care 35:12 (2012), 2515–2520.
4. JDRF Impact. http://www2.jdrf.org/site/DocServer/2016_JDRF_Fact_Sheet.pdf?docID=5143 [accessed 5.5.17].
5. Dabelea, D., Mayer-Davis, E.J., Saydah, S., et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311:17 (2014), 1778–1786.
6. Livingstone, S.J., Levin, D., Looker, H.C., et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 313:1 (2015), 37–44.
7. The Diabetes Control and Complications Trial, (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39 (2016), 686–693.
8. Miller, K.M., Foster, N.C., Beck, R.W., et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care 38:6 (2015), 971–978.
9. American Diabetes Association, Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes 2016. Diabetes Care 39:1 (2016), S52–S59.
10. Frandsen, C.S., Dejgaard, T.F., Madsbad, S., Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 4:9 (2016), 766–780.
11. George, P., McCrimmon, R.J., Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabetes Med 30:2 (2013), 179–188.
12. Liu, C., Wu, D., Zheng, X., et al. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 17:2 (2015), 142–148.
13. Libman, I.M., Miller, K.M., DiMeglio, L.A., et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 314:21 (2015), 2241–2250.
14. Tafuri, K.S., Godil, M.A., Lane, A.H., et al. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 5:4 (2013), 236–239.
15. Kuhadiya, N.D., Malik, R., Bellini, N.J., et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocrine Pract 19:6 (2013), 963–967.
16. Garg, S.K., Moser, E.G., Bode, B.W., et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocrine Pract 19:1 (2013), 19–28.
17. Rahmoune, H., Thompson, P.W., Ward, J.M., et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
18. Ferrannini, E., Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8 (2012), 495–502.
19. Bolinder, J., Ljunggren, O., Kullberg, J., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metabol 997 (2012), 1020–1031.
20. Madaan, T., Akhtar, M., Najmi, A.K., Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci 93 (2016), 244–252.
21. Chiang, J.L., Kirkman, M.S., Laffel, L.M., et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37 (2014), 2034–2054.
22. Zaccardi, F., Webb, D.R., Htike, Z.Z., et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 18:8 (2016), 783–794.
23. Chen, M., Xie, C.-G., Gao, H., et al. Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis. BMJ Open, 6(1), 2016, e010252.
24. Yang, X.P., Lai, D., Zhong, X.Y., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 70:10 (2014), 1149–1158.
25. Baker, W.L., Smyth, L.R., Riche, D.M., et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertension 8:4 (2014), 262–275.
26. Monami, M., Nardini, C., Mannucci, E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:5 (2014), 457–466.
27. Liakos, A., Karagiannis, T., Athanasiadou, E., et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16 (2014), 984–993.
28. Oelze, M., Kroller-Schon, S., Welschof, P., et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE, 9(11), 2014, e112394.
29. Cheng, S.T., Chen, L., Li, S.Y., et al. The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes. PLoS ONE, 11(1), 2016, e0147391.
30. Hatanaka, T., Ogawa, D., Tachibana, H., et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect, 4(4), 2016, e00239.
31. Henry, R.R., Thakkar, P., Tong, C., et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38 (2015), 2258–2265.
32. Kuhadiya, N.D., Ghanim, H., Mehta, A., et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 101:9 (2016), 3506–3515.
33. Sands, A.T., Zambrowicz, B.P., Rosenstock, J., et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38 (2015), 1181–1188.
34. Pieber, T.R., Famulla, S., Eilbracht, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17 (2015), 928–935.
35. Argento, N.B., Nakamura, K., Glycemic effects of SGLT-2 inhibitor canagliflozin in type 1 diabetes patients using the Dexcom G4 platinum CGM. Endocrine Pract 22:3 (2016), 315–322.
36. Perkins, B.A., Cherney, D.Z., Partridge, H., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37:5 (2014), 1480–1483.
37. Tamez, H.E., Tamez, A.L., Garza, L.A., et al. Dapagliflozin as adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metabol Disord, 14, 2015, 78.
38. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
39. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:5 (2014), 587–597.
40. Perkins, B.A., Cherney, D.Z., Soleymanlou, N., et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS ONE, 10(11), 2015, e0141085.
41. Rodbard, H.W., Peters, A.L., Slee, A., et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 40:2 (2017), 171–180.
42. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org.
43. Higgins, J.P.T., Thompson, S.G., Spiegelhalter, D.J., A re-evaluation of random-effects meta-analysis. J Roy Stat Soc 172:1 (2009), 137–159.
44. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(7), 2009, e1000097.
45. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
46. Chiang, J.L., Kirkman, M.S., Laffel, L.M.B., et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37 (2014), 2034–2054.
47. Tahara, A., Takasu, T., Yokono, M., et al. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 130:3 (2016), 159–169.
48. Edelman, S.V., Weyer, C., Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 4:2 (2004), 175–189.
49. Taylor, S.I., Blau, J.E., Rother, K.I., SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100:8 (2015), 2849–2852.
50. Driscoll, K.A., Corbin, K.D., Maahs, D.M., et al. Biopsychosocial aspects of weight management in type 1 diabetes: a review and next steps. Curr DiabRep, 17(8), 2017, 58.
51. Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from: https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm475553.htm [accessed 11.21.17].
52. Monami, M., Nreu, B., Zannoni, S., et al. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 130 (2017), 53–60.
53. Chen, J., Fan, F., Wang, J., et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep, 7, 2017, 44128.
54. Yang, Y., Pan, H., Wang, B., et al. Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Chin Med Sci J 32:1 (2017), 22–27.